Date: 2016-11-28
Type of information: R&D agreement
Compound: drug targeting hair cell regeneration
Company: Boehringer Ingelheim (Germany) China Southeast University (China)
Therapeutic area: Otorhinolaryngology - Regenerative medicine
Type agreement: R&D
Action mechanism:
Disease: hearing loss
Details: * On November 28, 2016, Boehringer Ingelheim and China Southeast University Institute of Life Sciences announced the start of a joint research project to develop new treatment approaches for hearing loss through regeneration of hair cells from inner ear stem cells. The new collaboration combines the expertise of Professor Renjie Chai, one of the worldwide leaders in the field of hearing loss, with Boehringer Ingelheim’s expertise in drug discovery and clinical development to pave the way for the development of much needed new treatment options for this condition. The new research collaboration in hearing loss is an initiative of Boehringer Ingelheim’s newly established organisation Research Beyond Borders (RBB). It complements a research collaboration with Kyoto University initiated earlier this year that focuses on utilising findings on hair cell regeneration in birds. Through the collaboration with China Southeast University, Boehringer Ingelheim will investigate key signaling pathways and proteins involved in regeneration in the inner ear to develop a drug discovery strategy to target hair cell regeneration and ultimately address the unmet medical need in hearing loss via regenerative medicine approaches.
Financial terms:
Latest news:
